These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 21917660

  • 1. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D, Goode KM, Cleland JG, Clark AL.
    Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660
    [Abstract] [Full Text] [Related]

  • 2. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM.
    Am J Cardiovasc Drugs; 2012 Dec 01; 12(6):415-26. PubMed ID: 23181944
    [Abstract] [Full Text] [Related]

  • 3. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators.
    J Am Coll Cardiol; 2012 May 29; 59(22):1938-45. PubMed ID: 22617188
    [Abstract] [Full Text] [Related]

  • 4. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N.
    Therapie; 2009 May 29; 64(2):111-4. PubMed ID: 19664404
    [Abstract] [Full Text] [Related]

  • 5. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M, Talajic M, Robertson M, Tardif JC, Ferrari R, Ford I, Steg PG, Fox K, BEAUTIFUL Investigators.
    Am J Cardiol; 2011 Mar 15; 107(6):805-11. PubMed ID: 21247517
    [Abstract] [Full Text] [Related]

  • 6. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
    Reil JC, Reil GH, Böhm M.
    Trends Cardiovasc Med; 2009 Jul 15; 19(5):152-7. PubMed ID: 20005474
    [Abstract] [Full Text] [Related]

  • 7. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure.
    Castagno D, Petrie MC, Claggett B, McMurray J.
    Eur Heart J; 2012 May 15; 33(9):1137-41. PubMed ID: 22408030
    [Abstract] [Full Text] [Related]

  • 8. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
    Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L.
    Eur J Heart Fail; 2010 Jan 15; 12(1):75-81. PubMed ID: 19892778
    [Abstract] [Full Text] [Related]

  • 9. Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period.
    Dierckx R, Cleland JG, Parsons S, Putzu P, Pellicori P, Dicken B, Boyalla V, Clark AL.
    JACC Heart Fail; 2015 Mar 15; 3(3):224-30. PubMed ID: 25650369
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J, Varela A.
    Am J Cardiovasc Drugs; 2009 Mar 15; 9 Suppl 1():9-12. PubMed ID: 20000882
    [Abstract] [Full Text] [Related]

  • 12. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
    Tardif JC, O'Meara E, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K, SHIFT Investigators.
    Eur Heart J; 2011 Oct 15; 32(20):2507-15. PubMed ID: 21875858
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2007 Oct 27; 84(8):988-96. PubMed ID: 17989604
    [Abstract] [Full Text] [Related]

  • 15. Age is not a significant risk factor for failed trial of beta-blocker therapy in older patients with chronic heart failure.
    Witham MD, Gillespie ND, Struthers AD.
    Age Ageing; 2004 Sep 27; 33(5):467-72. PubMed ID: 15217777
    [Abstract] [Full Text] [Related]

  • 16. Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?
    Roth S, Fernando C, Azeem S, Moe GW.
    Adv Ther; 2017 Jun 27; 34(6):1340-1348. PubMed ID: 28432646
    [Abstract] [Full Text] [Related]

  • 17. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov 27; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 18. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Nov 27; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan 27; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.